Four old syndrome names, one gene: how MYH9-related disease presents, what the blood film shows, how to tell it from other inherited macrothrombocytopenias, and why it is so often mistaken for immune thrombocytopenia.

- Gene: MYH9 (22q12.3) encodes non-muscle myosin heavy chain IIA (NMMHC-IIA); autosomal dominant
- One disease: May-Hegglin anomaly, Fechtner, Epstein and Sebastian syndromes are now grouped as MYH9-related disease (MYH9-RD)
- Constant feature: macrothrombocytopenia with bleeding milder than the count suggests
- Blood film: Döhle-like bodies in neutrophils are seen on routine stain in most patients but may be absent; immunofluorescence for NMMHC-IIA picks up all
- Later features: sensorineural deafness, proteinuric nephropathy, presenile cataracts, raised liver enzymes
- Pitfall: often misdiagnosed as immune thrombocytopenia
Pathology MCQ app · Android
Get the Pathology MCQ app
Practise haematology with a new MCQ every day.
- ❓Daily MCQ with explanations and streaks
- 🔬Virtual slides you pinch-zoom, with annotations
- 📚Your courses, notes and mocks in one place
The old syndromes
Mutant NMMHC-IIA disturbs the cytoskeleton of megakaryocytes, so proplatelet formation is ineffective and platelets are released too large and too few. The four classic syndromes differ only in which non-haematological features had appeared when they were described; they are now seen as one spectrum.
| Syndrome | Neutrophil inclusions (routine stain) | Nephritis | Deafness | Cataract |
|---|---|---|---|---|
| May-Hegglin anomaly | Yes (large, blue) | No | No | No |
| Sebastian syndrome | Yes (smaller, ill-defined) | No | No | No |
| Fechtner syndrome | Yes | Yes | Yes | Yes |
| Epstein syndrome | No (abnormal only on immunofluorescence) | Yes | Yes | No |
Laboratory features
- Giant platelets: many as large as red cells; mean platelet volume often cannot be measured.
- Döhle-like bodies: pale blue cytoplasmic inclusions in neutrophils, made of NMMHC-IIA aggregates. They can be small or invisible on a routine stain.
- Immunofluorescence: staining a blood smear for NMMHC-IIA is the most sensitive screen; the pattern (large clumps, small clumps or diffuse) correlates with the mutation.
- Platelet count: automated counters undercount giant platelets as red cells; a manual or optical count is more accurate.
- Platelet function: usually near normal, so bleeding is mild despite low counts.
- Confirmation: MYH9 sequencing.
Lifelong thrombocytopenia with giant platelets and a family history should prompt a careful film before calling it immune thrombocytopenia. Misdiagnosis leads to useless steroids, immunoglobulin or even splenectomy.
Differential diagnosis: inherited macrothrombocytopenias
Giant platelets are not specific to MYH9-RD. Read the film for white-cell inclusions and granule content, then use function and flow studies to separate the others.
| Disorder | Gene and inheritance | Blood film clue | Bleeding and platelet function | Key test |
|---|---|---|---|---|
| MYH9-related disease | MYH9; autosomal dominant | Giant platelets; Döhle-like bodies in neutrophils (may be absent) | Mild bleeding; function near normal | NMMHC-IIA immunofluorescence; MYH9 sequencing |
| Bernard-Soulier syndrome | GP1BA, GP1BB, GP9; usually autosomal recessive | Giant platelets; no white-cell inclusions | Moderate to severe mucocutaneous bleeding; no ristocetin agglutination, not corrected by normal plasma | Flow cytometry: reduced CD42b and CD42a |
| Gray platelet syndrome | NBEAL2; autosomal recessive | Large, pale grey, agranular platelets | Mild to moderate bleeding; alpha-granule deficiency | Electron microscopy; marrow fibrosis and splenomegaly are clues |
| GATA1-related disease | GATA1; X-linked | Large, grey platelets with anaemia; dyserythropoiesis in marrow | Variable bleeding | GATA1 sequencing |
| ACTN1 or TUBB1-related | ACTN1, TUBB1; autosomal dominant | Large platelets; no inclusions | Usually asymptomatic; function normal | Sequencing (diagnosis of exclusion) |
| Immune thrombocytopenia (mimic) | Acquired | Platelets may be mildly large, not giant; no inclusions | Bleeding tracks the count | Exclusion; responds to steroids or immunoglobulin |
Start with platelet size. Small platelets point to Wiskott-Aldrich syndrome. Giant platelets with neutrophil inclusions point to MYH9-RD. Giant platelets without inclusions need ristocetin studies, granule assessment and flow cytometry.
Organ involvement and management
| Organ | Feature | Note |
|---|---|---|
| Ear | Sensorineural deafness | The commonest extra-haematological feature; cochlear implants work well |
| Kidney | Proteinuric nephropathy progressing to kidney failure | Linked especially to mutations in the head (motor) domain |
| Eye | Presenile cataract | Less common |
| Liver | Mildly raised liver enzymes | Usually benign |
Mutations in the head domain (for example at R702) carry the highest risk of nephropathy and early deafness; most tail-domain mutations cause a milder, mainly haematological picture.
- Avoid steroids, immunoglobulin and splenectomy; they do not help.
- Before surgery or delivery: platelet transfusion if needed, or a thrombopoietin receptor agonist such as eltrombopag to raise the count.
- Monitor hearing and urine protein regularly; start an ACE inhibitor or ARB for proteinuria.
- Offer genetic counselling: 50% risk to each child.
Practice questions
A young man has lifelong thrombocytopenia, giant platelets, blue inclusions in neutrophils, hearing loss and proteinuria. Which protein is abnormal?
Show answer
A patient has macrothrombocytopenia, neutrophil Döhle-like bodies, nephritis, sensorineural deafness and cataract. Which historical syndrome does this describe?
Show answer
Why may an automated impedance analyser report a falsely low platelet count in MYH9-related disease?
Show answer
Which test on a peripheral blood smear detects MYH9-related disease even when Döhle-like bodies are not visible on routine stain?
Show answer
A child is found to carry an MYH9 R702 head-domain mutation. Which complication should the family be warned about?
Show answer
A 22-year-old has had a platelet count of 35 × 10⁹/L since childhood. Steroids, immunoglobulin and splenectomy for presumed ITP failed. Her mother is deaf with a low platelet count, and the film shows large platelets. What is the best next step?
Show answer
A child has giant platelets and mucocutaneous bleeding. Ristocetin does not agglutinate the platelets, and normal plasma does not correct it. There are no neutrophil inclusions. What is the diagnosis?
Show answer
A patient has large, pale grey platelets that lack granules on a Romanowsky stain, with marrow fibrosis and splenomegaly. Which gene is most likely mutated?
Show answer
A woman with confirmed MYH9-related disease and a platelet count of 25 × 10⁹/L needs elective surgery. Which is the most appropriate way to raise the count beforehand?
Show answer
Which statement about MYH9-related disease is correct?
Show answer
Pathology MCQ app · Android
Get the Pathology MCQ app
Practise a slide and an MCQ every day, even when you are away from your desk.
- ❓Daily MCQ with explanations and streaks
- 🔬Virtual slides you pinch-zoom, with annotations
- 📚Your courses, notes and mocks in one place
- MYH9 encodes NMMHC-IIA; the disease is autosomal dominant.
- May-Hegglin, Sebastian, Fechtner and Epstein are one spectrum: MYH9-related disease.
- Giant platelets are constant; Döhle-like bodies are usually but not always visible, and immunofluorescence finds the rest.
- Deafness, nephritis and cataract may follow, mainly with head-domain mutations such as R702.
- Do not mistake it for immune thrombocytopenia; count platelets manually and avoid steroids and splenectomy.
- Bernard-Soulier syndrome, gray platelet syndrome and GATA1-related disease are the main giant-platelet mimics.
Pecci A, Ma X, Savoia A, Adelstein RS. MYH9: structure, functions and role of non-muscle myosin IIA in human disease. Gene 2018;664:152–167 · Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011;154:161–174 · Pecci A, Klersy C, Gresele P, et al. MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations. Hum Mutat 2014;35:236–247 · Pecci A, Gresele P, Klersy C, et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010;116:5832–5837 · Bain BJ. Blood Cells: A Practical Guide, 6th ed. Wiley-Blackwell; 2022
High-Yield, Board-Style Image MCQs & Interactive Whole Slide Images
High-resolution virtual microscopy with questions aligned to ABP, FRCPath, NEET-SS, DM Hematopathology and MD/DNB.
Pathology MCQ


Leave a Reply